Adlai shares surge 13.35% intraday after securing $140M private equity financing led by Cormorant Asset Management and Columbia Threadneedle Investments to accelerate RAS-targeted cancer therapies.
ByAinvest
Wednesday, Feb 4, 2026 10:17 am ET1min read
ANL--
Adlai surged 13.35% intraday, as the company announced a $140 million private equity financing led by Cormorant Asset Management and Columbia Threadneedle Investments, enhancing its financial strength and accelerating the development of RAS-targeted cancer therapies. The company is a clinical-stage biotechnology firm focused on developing innovative cancer treatments.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet